Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
AstraZeneca
Boehringer Ingelheim
Express Scripts

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,862,833

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,862,833 protect, and when does it expire?

Patent 7,862,833 protects FENTORA and is included in one NDA.

This patent has sixty-three patent family members in twenty-nine countries.

Summary for Patent: 7,862,833
Title:Effervescent oral opiate dosage forms and methods of administering opiates
Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
Inventor(s): Moe; Derek (Maple Grove, MN)
Assignee: Cima Labs, Inc. (Eden Prairie, MN)
Application Number:11/026,759
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,862,833
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Delivery; Composition;

Drugs Protected by US Patent 7,862,833

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-001 Sep 25, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-002 Sep 25, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-003 Sep 25, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-004 Sep 25, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-005 Sep 25, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,862,833

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047999   Start Trial
Argentina 048000   Start Trial
Argentina 048029   Start Trial
Argentina 098347   Start Trial
Austria 498395   Start Trial
Austria 500821   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Boehringer Ingelheim
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.